The Innovative Medicines Initiative (IMI) has launched its 100th project in the form of Hypo-RESOLVE, a 4 year, EUR 26.8 million project on diabetes. The milestone comes as IMI celebrates its 10th anniversary with a series of events and activities. The IMI project portfolio is diverse; many projects, like Hypo-RESOLVE, focus on specific health issues such as diabetes, neurological conditions (including dementia, depression, and pain), cancer, auto-immune diseases (such as rheumatoid arthritis), and infectious diseases (including antimicrobial resistance and Ebola).
The European Commission is putting forward a set of measures to increase the availability of data in the EU, building on previous initiatives to boost the free flow of non-personal data in the Digital Single Market. Data-driven innovation is a key enabler of market growth, job creation, particularly for SMEs and startups, and the development of new technologies.
European Commission has put forward a proposal to boost cooperation amongst EU Member States for assessing health technology. Greater transparency will empower patients, by ensuring their access to information on the added clinical value of new technology that could potentially benefit them. Page 10 of 46